Binding Mode of Cyclic Chemerin‐9 Peptide and ChemerinS157 Protein at CMKLR1
ChemBioChem · 2025
DOI: 10.1002/cbic.202400695 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Tina Schermeng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany. Hauptthemen laut MEDLINE: Chemokines, Receptors, Chemokine, Intercellular Signaling Peptides and Proteins, Peptides, Cyclic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Research Foundation, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The chemokine‐like receptor 1 (CMKLR1) is activated by the adipokine and chemoattractant protein chemerin. Cryo‐EM structures of chemerin‐9‐CMKLR1‐Gi have been published, where chemerin‐9 is the nonapeptide of the C terminus of chemerinS157. Chemerin‐9 is as active as the full‐length protein in Ca 2+ ‐release but shows differences in equilibrium read‐outs. An equally potent cyclic chemerin‐9 variant (cC9) was reported previously. Now, we have built a computational model of CMKLR1 to investigate the binding mode of cC9 and chemerinS157 in comparison to chemerin‐9. Differences were investigated using CMKLR1 variants. Double‐mutant cycle analysis identified CMKLR1‐F2.53 as the relevant position for Phe8‐binding of cC9. Energy contribution revealed slight differences in Phe8‐binding to CMKLR1‐F2.53 and space for larger residues. This was confirmed as the chemerin‐9 variant with 1‐naphthyl‐L‐alanine at position 8 showed a 4‐fold increased potency of 2 nM (pEC 50 =8.6±0.15). While chemerin‐9 and cC9 share their interactions at the CMKLR1, chemerinS157 tolerates most mutations of CMKLR1 in the deep binding site. The computational model of chemerinS157 suggests a β‐sheet interaction between the N‐terminal CMKLR1‐segment I25VVL28 and the β‐sheet D108KVLGRLVH116 of ChemS157, which was confirmed experimentally. Our data add to the knowledge by identifying the binding mode of chemerinS157 and cC9 at CMKLR1, facilitating the future structure‐based drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany.
- Institute for Drug Discovery, Leipzig University Medical School, Brüderstraße 34, 04103, Leipzig, Germany.
- Center for Scalable Data Analytics and Artificial Intelligence ScaDS.AI, Leipzig University, Humboldstraße 25, 04105, Leipzig, Germany.
- Department of Chemistry and Pharmacology, Vanderbilt University, 5144B MRBIII, Nashville, Tennessee, 37235, United States.
ORCID-Profile: Tina Schermeng, Fabian Liessmann, Carla Katharina Ambrosius, Jens Meiler, Annette G Beck-Sickinger
Förderung
- German Research Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Schermeng, T., Liessmann, F., Katharina Ambrosius, C., Meiler, J., & Beck-Sickinger, A. G. (2025). Binding Mode of Cyclic Chemerin‐9 Peptide and ChemerinS157 Protein at CMKLR1. ChemBioChem. https://doi.org/10.1002/cbic.202400695
Vancouver
Schermeng T, Liessmann F, Katharina Ambrosius C, Meiler J, Beck-Sickinger AG. Binding Mode of Cyclic Chemerin‐9 Peptide and ChemerinS157 Protein at CMKLR1. ChemBioChem. 2025. doi:10.1002/cbic.202400695
BibTeX
@article{Schermeng2025,
author = {Schermeng, Tina and Liessmann, Fabian and Katharina Ambrosius, Carla and Meiler, Jens and Beck-Sickinger, Annette G},
title = {Binding Mode of Cyclic Chemerin‐9 Peptide and ChemerinS157 Protein at CMKLR1},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202400695}
}
EUVIMED